$DGX

QUEST DIAGNOSTICS INC

Quest Diagnostics provides diagnostic information services to physicians, hospitals, patients and consumers, health plans, employers, government agencies, pharmaceutical companies and other healthcare organizations. Its Diagnostic Information Services business performs laboratory testing and provides related insights, including routine, specialized and advanced tests in areas such as oncology, neurology, genetics and infectious diseases. Its Diagnostic Solutions group includes risk assessment services for insurers and healthcare IT solutions for providers and payers. Services are primarily offered under the Quest Diagnostics brand, as well as AmeriPath, Dermpath Diagnostics, ExamOne and Quanum. Quest makes money by performing laboratory tests and providing related services, including hospital laboratory management and testing, consumer-initiated tests through QuestHealth.com, and risk assessment and healthcare IT solutions. It also provides data analytics and diagnostic services to healthcare organizations and other customers. The company conducts substantially all of its business in the United States and is headquartered in Secaucus, New Jersey.

1
1
1
—
$11.9M
Doherty Catherine T.
100%
See all $DGX insider activity →
Low

Deppe Michael J sold $3.1M of DGX

Deppe Michael J (SVP, Corp. Controller & CAO) sold 11,776 shares of QUEST DIAGNOSTICS INC (DGX) at $260.17 ($3.06M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.

Quest settles federal claims over VIP Giants access for doctors

Quest Diagnostics (DGX) settled federal claims for $13,014,576 plus interest, resolving allegations of illegal kickbacks to healthcare providers via New York Giants events to induce patient referrals. The settlement covers 2013-2022 and includes a 5-year Corporate Integrity Agreement. The case was initiated by whistleblowers, who will share $2,472,769 of the recovery.

Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.

DGX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning DGX (QUEST DIAGNOSTICS INC). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.

Recent DGX coverage spans insider activity, regulation and corporate actions.

In the last 30 days, DGX insiders filed 13 SEC Form 4 transactions — no purchases and 13 sales ($11.9M). The most active reporter was Doherty Catherine T., Executive Vice President, with 7 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving DGX

  • This is an insider open-market sale under a 10b5-1 plan, which is typically not a strong standalone bearish signal but can slightly affect sentiment.

    SEC EDGAR · Nov 16, 2026

  • The settlement introduces a new liability and may prompt investors to reassess legal risk.

    finance.yahoo.com · Nov 15, 2026

  • Quest’s guidance increase is tied to faster testing-volume growth and partner-driven volume, which can support earnings expectations if Medicare PAMA risk is manageable.

    finance.yahoo.com · Nov 13, 2026

  • The insider sale may signal reduced confidence and could pressure the stock short term.

    SEC EDGAR · Nov 13, 2026

  • Dividend announcement may provide modest upside pressure as income‑focused investors add interest.

    prnewswire.com · Nov 10, 2026

AlphAI scores every news story that mentions DGX with an AI model for sentiment and relevance, and aggregates insider trades from QUEST DIAGNOSTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DGX

Score

Quest settles federal claims over VIP Giants access for doctors

Quest Diagnostics (DGX) settled federal claims for $13,014,576 plus interest, resolving allegations of illegal kickbacks to healthcare providers via New York Giants events to induce patient referrals. The settlement covers 2013-2022 and includes a 5-year Corporate Integrity Agreement. The case was initiated by whistleblowers, who will share $2,472,769 of the recovery.

Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.

Artificial Intelligence at Quest Diagnostics – Two Use Cases

Quest Diagnostics reported $11B in 2025 revenues, processing 244M test requisitions. It met its 3% cost savings target via AI and automation. Quest acquired PathAI Diagnostics and partnered with Google Cloud for AI advancements. The company uses AI in Pap test slide reviews and customer service, aiming to improve efficiency and productivity.

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

Related tickers